Skip to main content

Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis

Abstract

Rationale

Major depressive episodes are severe mood episodes which occur both in major depressive disorder and bipolar I and II disorder. Major depressive episodes are characterized by debilitating symptoms that often persist and interfere with typical daily functioning. Various treatments exist for major depressive episodes; however, most primary pharmacologic treatments may take weeks to months to provide relief from depressive symptoms. Ketamine is a demonstrated treatment for major depressive episodes, as relief from depressive symptoms can occur rapidly following treatment.

Objectives

Prior meta-analyses have been conducted to analyze the effectiveness of ketamine for the treatment of major depressive episodes, but at the time of this writing, no meta-analysis had been conducted to observe ketamine treatment efficacy beyond 2 weeks.

Methods

The present meta-analysis evaluated the efficacy of ketamine for the treatment of major depressive episodes; observations of depressive episode severity were analyzed at 2, 4, and 6-weeks post-treatment.

Results

The present meta-analysis observed large effects at 2 weeks (g = −1.28), 4 weeks, (g = −1.28), and 6 weeks (g = −1.36) post-treatment.

Conclusions

The results from the present meta-analysis indicate that ketamine can be an effective pharmacologic intervention for major depressive episodes, with treatment effects lasting up to 6 weeks post-ketamine administration, which has many positive implications for treatment.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Data availability

The datasets generated during and/or analyzed during the current study are available in the OSF repository, https://osf.io/qwbmh/.

References

*References marked with an asterisk indicate studies included in the meta-analysis. +References marked with a plus symbol indicate studies that were imputed and reported in the Supplement

  1. *aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67(2):139–145. https://doi.org/10.1016/j.biopsych.2009.08.038

    CAS  Article  Google Scholar 

  2. Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH (2016) Ketamine’s mechanism of action: A path to rapid-acting antidepressants. Depress Anxiety 33(8):689–697. https://doi.org/10.1002/da.22501

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. *+Albott CS, Lim KO, Forbes MK, Erbes C, Tye SJ, Grabowski JG, Thuras P, Batres-y-Carr TM, Wels J, Shiroma PR (2018) Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry 79(3):17m11634. https://doi.org/10.4088/JCP.17m11634

    Article  PubMed  Google Scholar 

  4. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC

  5. *Anderson IM, Blamire A, Branton T, Brigadoi S, Clark R, Downey D, Dunn G, Easton A, Elliott R, Elwell C, Hayden K, Holland F, Karim S, Lowe J, Loo C, Nair R, Oakley T, Prakash A, Sharma PK, Williams SR, McAllister-Williams RH (2017) Randomized controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study). Efficacy Mech Eval 4(2):1–112. https://doi.org/10.3310/eme04020

    Article  Google Scholar 

  6. Andrade C (2017) Ketamine for Depression, 4: In what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry 78(7):e852–e857. https://doi.org/10.4088/JCP.17f11738

    Article  PubMed  Google Scholar 

  7. Aust S, Gärtner M, Basso L, Otte C, Wingenfeld K, Chae WR, Heuser-Collier I, Regen F, Cosma NC, van Hall F, Grimm S, Bajbouj M (2019) Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. Eur Neuropsychopharmacol 29(4):529–538. https://doi.org/10.1016/j.euroneuro.2019.02.005

    CAS  Article  PubMed  Google Scholar 

  8. Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, Brutsché NE, Ameli R, Furey ML, Zarate CA (2014) Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety. J Psychiatr Res 58:161–166. https://doi.org/10.1016/j.jpsychires.2014.07.027

    Article  PubMed  Google Scholar 

  9. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis. John Wiley

  10. Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK (2014) Ketamine as the prototype glutamatergic antidepressant: Pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 4(2):75–99. https://doi.org/10.1177/2045125313507739

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. *Cao Z, Lin C-T, Ding W, hen, M.-H., Li, C.-T., & Su, T.-P. (2019) Identifying ketamine responses in treatment-resistant depression using a wearable forehead EEG. IEEE Trans Biomed Eng 66(6):1668–1679. https://doi.org/10.1109/TBME.2018.2877651

    Article  Google Scholar 

  12. *Chen M-H, Li C-T, Lin W-C, Hong C-J, Tu P-C, Bai Y-M, Cheng C-M, Su T-P (2018) Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion. J Affect Disord 241:1–7. https://doi.org/10.1016/j.jad.2018.07.033

    CAS  Article  PubMed  Google Scholar 

  13. *+Chen M-H, Cheng C-M, Gueorguieva R, Lin W-C, Li C-T, Hong C-J, Tu P-C, Bai Y-M, Tsai S-J, Krystal JH, Su T-P (2019a) Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: A double-blind randomized placebo–control study. Neuropsychopharmacology 44(12):2112–2118. https://doi.org/10.1038/s41386-019-0480-y

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. *Chen M-H, Lin W-C, Wu H-J, Cheng C-M, Li C-T, Hong C-J, Tu P-C, Bai Y-M, Tsai S-J, Su T-P (2019b) Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). J Affect Disord 251:162–169. https://doi.org/10.1016/j.jad.2019.03.075

    CAS  Article  PubMed  Google Scholar 

  15. Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Earlbaum Associates

  16. *Costi S, Soleimani L, Glasgow A, Brallier J, Spivack J, Schwartz J, Levitch CF, Richards S, Hoch M, Wade E, Welch A, Collins KA, Feder A, Iosifescu DV, Charney DS, Murrough JW (2019) Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: A randomized controlled trial. Neuropsychopharmacology 44(10):1812–1819. https://doi.org/10.1038/s41386-019-0365-0

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. Coyle CM, Laws KR (2015) The use of ketamine as an antidepressant: A systematic review and meta-analysis: Ketamine as an Antidepressant. Hum Psychopharmacol Clin Exp 30(3):152–163. https://doi.org/10.1002/hup.2475

    CAS  Article  Google Scholar 

  18. *Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiat 75(2):139–148. https://doi.org/10.1001/jamapsychiatry.2017.3739

    Article  Google Scholar 

  19. *Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67(8):793–802. https://doi.org/10.1001/archgenpsychiatry.2010.90

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. *Domany Y, Shelton RC, McCullumsmith CB (2020) Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial. Depress Anxiety 37(3):224–233. https://doi.org/10.1002/da.22975

    CAS  Article  PubMed  Google Scholar 

  21. *Dong J, Min S, Qiu H, Chen Q, Ren L (2019) Intermittent administration of low dose ketamine can shorten the course of electroconvulsive therapy for depression and reduce complications: A randomized controlled trial. Psychiatry Res 281:112573. https://doi.org/10.1016/j.psychres.2019.112573

    Article  PubMed  Google Scholar 

  22. Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, Wolfson P (2019) Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs 51(2):29–198. https://doi.org/10.1080/02791072.2019.1587556

    Article  Google Scholar 

  23. Duman RS, Sanacora G, Krystal JH (2019) Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron 102(1):75–90. https://doi.org/10.1016/j.neuron.2019.03.013

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. *Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI (2018) Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 25:1592–1603. https://doi.org/10.1038/s41380-018-0256-5

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. FDA (2019) Medication guide: Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf. Accessed 24 Jan 2021

  27. Finnegan M, Galligan T, Ryan K, Shanahan E, Harkin A, Daly L, McLoughlin DM (2019) Ketamine versus midazolam for depression relapse prevention following successful electroconvulsive therapy: A randomized controlled pilot trial. The Journal of ECT 35(2):115–121. https://doi.org/10.1097/YCT.0000000000000560

    CAS  Article  PubMed  Google Scholar 

  28. *Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M (2019) Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res 110:166–171. https://doi.org/10.1016/j.jpsychires.2019.01.010

    Article  PubMed  PubMed Central  Google Scholar 

  29. *Gálvez V, Li A, Huggins C, Glue P, Martin D, Somogyi AA, Alonzo A, Rodgers A, Mitchell PB, Loo CK (2018) Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomized controlled trial. J Psychopharmacol 32(4):397–407. https://doi.org/10.1177/0269881118760660

    CAS  Article  PubMed  Google Scholar 

  30. Godlewska BR, Harmer CJ (2020). Cognitive neuropsychological theory of antidepressant action: a modern-day approach to depression and its treatment. Psychopharmacology (Berl). https://doi.org/10.1007/s00213-019-05448-0

  31. Goldstein DJ, Potter WZ, Ciraulo DA, Shader RI (2011) Biological theories of depression and implications for current and new treatments. In: Ciraulo DA, Shader RI (eds) Pharmacotherapy of Depression. Humana Press, Totowa, pp 1–32. https://doi.org/10.1007/978-1-60327-435-7_1

    Chapter  Google Scholar 

  32. Han Y, Chen J, Zou D, Zheng P, Li Q, Wang H, Li P, Zhou X, Zhang Y, Liu Y, Xie P (2016) Efficacy of ketamine in the rapid treatment of major depressive disorder: A meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat 12:2859–2867. https://doi.org/10.2147/NDT.S117146

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. Higgins JPT (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557

    Article  PubMed  PubMed Central  Google Scholar 

  34. Horvitz-Lennon M, Normand ST, Frank RG, Goldman HH (2003) “Usual care” for major depression in the 1990s: Characteristics and expert-estimated outcomes. Am J Psychiatr 160:720–726. https://doi.org/10.1176/appi.ajp.160.4.720

    Article  PubMed  Google Scholar 

  35. *Hu Y-D, Xiang Y-T, Fang J-X, Zu S, Sha S, Shi H, Ungvari GS, Correll CU, Chiu HFK, Xue Y, Tian T-F, Wu A-S, Ma X, Wang G (2016) Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: Results from a randomized, placebo-controlled 4-week study. Psychol Med 46(3):623–635. https://doi.org/10.1017/S0033291715002159

    Article  PubMed  Google Scholar 

  36. *Ibrahim L, DiazGranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate CA (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37(6):1526–1533. https://doi.org/10.1038/npp.2011.338

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. *Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, Brutsche NE, Zarate CA (2014) Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry 75(09):e932–e938. https://doi.org/10.4088/JCP.14m09049

    CAS  Article  PubMed  Google Scholar 

  38. *Kantrowitz JT, Halberstam B, Gangwisch J (2015) Single-dose ketamine followed by daily d-cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry 76(06):737–738. https://doi.org/10.4088/JCP.14l09527

    Article  PubMed  Google Scholar 

  39. *Kheirabadi G, Vafaie M, Kheirabadi D, Mirlouhi Z, Hajiannasab R (2019) Comparative effect of intravenous ketamine and electroconvulsive therapy in major depression: A randomized controlled trial. Adv Biomed Res 8(1):25. https://doi.org/10.4103/abr.abr_166_18

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. *+Kheirkhah F, Tayyebi G, Rabiee SM, Moghadamnia A-A, Bijani A (2018) Efficacy of different doses of ketamine as a bolus in major depressive disorder. Caspian J Intern Med 9(3):220–227. https://doi.org/10.22088/cjim.9.3.220

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU (2016) Single-dose infusion ketamine and non-ketamine N -methyl- d -aspartate receptor antagonists for unipolar and bipolar depression: A meta-analysis of efficacy, safety and time trajectories. Psychol Med 46(7):1459–1472. https://doi.org/10.1017/S0033291716000064

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  42. *+Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA (2014) Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 4(10):e469–e469. https://doi.org/10.1038/tp.2014.105

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. *+Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA (2015) Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol 29(5):596–607. https://doi.org/10.1177/0269881114568041

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. Lee EE, Della Selva MP, Liu A, Himelhoch S (2015) Ketamine as a novel treatment for major depressive disorder and bipolar depression: A systematic review and quantitative meta-analysis. Gen Hosp Psychiatry 37(2):178–184. https://doi.org/10.1016/j.genhosppsych.2015.01.003

    Article  PubMed  Google Scholar 

  45. *Lenze EJ, Farber NB, Kharasch E, Schweiger J, Yingling M, Olney J, Newcomer JW (2016) Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. World J Biol Psychiatry 17(3):230–238. https://doi.org/10.3109/15622975.2016.1142607

    Article  PubMed  PubMed Central  Google Scholar 

  46. *Liu W, Zhou Y, Zheng W, Wang C, Zhan Y, Lan X, Zhang B, Li H, Chen L, Ning Y (2019) Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression. J Affect Disord 259:1–6. https://doi.org/10.1016/j.jad.2019.08.012

    CAS  Article  PubMed  Google Scholar 

  47. *Loo CK, Katalinic N, Garfield JBB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R (2012) Neuropsychological and mood effects of ketamine in electroconvulsive therapy: A randomised controlled trial. J Affect Disord 142(1–3):233–240. https://doi.org/10.1016/j.jad.2012.04.032

    CAS  Article  PubMed  Google Scholar 

  48. *+Loo CK, Gálvez V, O’Keefe E, Mitchell PB, Hadzi-Pavlovic D, Leyden J, Harper S, Somogyi AA, Lai R, Weickert CS, Glue P (2016) Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand 134(1):48–56. https://doi.org/10.1111/acps.12572

    CAS  Article  PubMed  Google Scholar 

  49. *Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA, Cassarly C, Zarate CA (2012) Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression: Bipolar depression and ketamine response. Bipolar Disord 14(8):880–887. https://doi.org/10.1111/bdi.12003

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW (2015) A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45(4):693–704. https://doi.org/10.1017/S0033291714001603

    CAS  Article  PubMed  Google Scholar 

  51. *McMillan R, Sumner R, Forsyth A, Campbell D, Malpas G, Maxwell E, Deng C, Hay J, Ponton R, Sundram F, Muthukumaraswamy S (2020) Simultaneous EEG/fMRI recorded during ketamine infusion in patients with major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 99:109838. https://doi.org/10.1016/j.pnpbp.2019.109838

    CAS  Article  Google Scholar 

  52. Minichino A, Senior M, Brondino N, Zhang SH, Godwlewska BR, Burnet PWJ, Cipriani A, Lennox BR (2019) Measuring disturbance of the endocannabinoid system in psychosis: A systematic review and meta-analysis. JAMA Psychiat 76(9):914–923. https://doi.org/10.1001/jamapsychiatry.2019.0970

    Article  Google Scholar 

  53. *+Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, Lener M, Kautz M, Kim J, Stern JB, Price RB, Perez AM, Brallier JW, Rodriguez GJ, Goodman WK, Iosifescu DV, Charney DS (2015) Ketamine for rapid reduction of suicidal ideation: A randomized controlled trial. Psychol Med 45(16):3571–3580. https://doi.org/10.1017/S0033291715001506

    CAS  Article  PubMed  Google Scholar 

  54. National Institute of Mental Health (2019) Major depression. https://www.nimh.nih.gov/site-info/citing-nimh-information-and-publications.shtml. Accessed 8 Aug 2019

  55. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. Am J Psychiatr 172(10):950–966. https://doi.org/10.1176/appi.ajp.2015.15040465

    Article  PubMed  Google Scholar 

  56. *Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA (2015) Ketamine’s antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Int J Neuropsychopharmacol 18(1):pyu039. https://doi.org/10.1093/ijnp/pyu039

    CAS  Article  Google Scholar 

  57. *Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, Steffens DC, Adler C, McShane R, Gaillard R, Wilkinson ST, Singh JB (2020) Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3. Am J Geriatr Psychiatry 28(2):121–141. https://doi.org/10.1016/j.jagp.2019.10.008

    Article  PubMed  Google Scholar 

  58. Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N (2017) Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: A systematic review and network meta-analysis. Curr Med Res Opin 33(4):701–711. https://doi.org/10.1080/03007995.2016.1277201

    CAS  Article  PubMed  Google Scholar 

  59. *Pérez-Esparza R, Corona T, Ruiz-García RG, Oñate-Cadena N, de la Fuente-Sandoval C, Ramírez-Bermúdez J (2018) Time until relapse after augmentation with single-dose ketamine in treatment-resistant depression: Letters to the Editor. Psychiatry Clin Neurosci 72(8):623–623. https://doi.org/10.1111/pcn.12675

    Article  PubMed  Google Scholar 

  60. Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, Owoeye O, Batten LA, Blier P (2019) Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. Am J Psychiatr 176(5):401–409. https://doi.org/10.1176/appi.ajp.2018.18070834

    Article  PubMed  Google Scholar 

  61. Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66(5):522–526. https://doi.org/10.1016/j.biopsych.2009.04.029

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  62. R Core Team (2019) R: A language and environment for statistical computing. Retrieved from https://www.R-project.org/

  63. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, Mann JJ, Brunner D, Hen R (1998) Serotonin receptor 1A knockout: An animal model of anxiety-related disorder. Proc Natl Acad Sci 95(24):14476–14481. https://doi.org/10.1073/pnas.95.24.14476

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  64. Rohatgi A (2019) WebPlotDigitizer. https://automeris.io/WebPlotDigitizer/. Accessed 8 Aug 2019

  65. Romeo B, Choucha W, Fossati P, Rotge J-Y (2015) Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res 230(2):682–688. https://doi.org/10.1016/j.psychres.2015.10.032

    CAS  Article  PubMed  Google Scholar 

  66. Saligan LN, Farmer C, Ballard ED, Kadriu B, Zarate CA (2019) Disentangling the association of depression on the anti-fatigue effects of ketamine. J Affect Disord 244:42–45. https://doi.org/10.1016/j.jad.2018.10.089

    CAS  Article  PubMed  Google Scholar 

  67. Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI (2020) Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord 260:131–139. https://doi.org/10.1016/j.jad.2019.09.017

    CAS  Article  PubMed  Google Scholar 

  68. Schwartz J, Murrough JW, Iosifescu DV (2016) Ketamine for treatment-resistant depression: Recent developments and clinical applications: Table 1. Evid Based Ment Health 19(2):35–38. https://doi.org/10.1136/eb-2016-102355

    Article  PubMed  Google Scholar 

  69. Shelton R (2016) *A study of ketamine in patients with treatment-resistant depression (Clinicaltrials.gov Identifier NCT01627782). https://clinicaltrials.gov/ct2/show/NCT01627782. Accessed 8 Aug 2019

  70. Shiroma PR (2019) *+Efficacy of repeated ketamine infusions for treatment-resistant depression (Clinicaltrials.gov Identifier NCT02360280). https://clinicaltrials.gov/ct2/show/NCT02360280. Accessed 8 Aug 2019

  71. *Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, Lim KO (2014) Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 155:123–129. https://doi.org/10.1016/j.jad.2013.10.036

    CAS  Article  PubMed  Google Scholar 

  72. Short B, Fong J, Galvez V, Shelker W, Loo CK (2018) Side-effects associated with ketamine use in depression: A systematic review. Lancet Psychiatry 5(1):65–78. https://doi.org/10.1016/S2215-0366(17)30272-9

    Article  PubMed  PubMed Central  Google Scholar 

  73. *Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L (2016) A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatr 173(8):816–826. https://doi.org/10.1176/appi.ajp.2016.16010037

    Article  PubMed  Google Scholar 

  74. *Sinyor M, Williams M, Belo S, Orser B, Vincent M, Mah L, Zarate C, Castel S, Levitt AJ, Schaffer A (2018) Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting. J Affect Disord 241:103–109. https://doi.org/10.1016/j.jad.2018.07.073

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  75. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR (2009) Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ 338(9 1):b2393–b2393. https://doi.org/10.1136/bmj.b2393

    Article  PubMed  PubMed Central  Google Scholar 

  76. Stockmeier C (1997) Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 16(2):162–173. https://doi.org/10.1016/S0893-133X(96)00170-4

    CAS  Article  PubMed  Google Scholar 

  77. *Su T-P, Chen M-H, Li C-T, Lin W-C, Hong C-J, Gueorguieva R, Tu P-C, Bai Y-M, Cheng C-M, Krystal JH (2017) Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology 42(13):2482–2492. https://doi.org/10.1038/npp.2017.94

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  78. *Thakurta R, Ray P, Kanji D, Das R, Bisui B, Singh OP (2012) Rapid antidepressant response with ketamine: Is it the solution to resistant depression? Indian J Psychol Med 34(1):56–60. https://doi.org/10.4103/0253-7176.96161

    Article  PubMed  PubMed Central  Google Scholar 

  79. Wampold BE, Minami T, Baskin TW, Tierney SC (2002) A meta-(re)analysis of the effects of cognitive therapy versus ‘other therapies’ for depression. J Affect Disord 618:159–165. https://doi.org/10.1016/s0165-0327(00)00287-1

    Article  Google Scholar 

  80. *Wilkinson ST, Sanacora G, Bloch MH (2017a) Hippocampal volume changes following electroconvulsive therapy: A systematic review and meta-analysis. Biol Psychiatry Cogn Neurosci Neuroimaging 2(4):327–335. https://doi.org/10.1016/j.bpsc.2017.01.011

    Article  PubMed  PubMed Central  Google Scholar 

  81. *Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, Sanacora G (2017b) Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosom 86(3):162–167. https://doi.org/10.1159/000457960

    Article  PubMed  Google Scholar 

  82. *Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons DM, Rodriguez CI, Schatzberg AF (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatr 175(12):1205–1215. https://doi.org/10.1176/appi.ajp.2018.18020138

    Article  PubMed  Google Scholar 

  83. World Health Organization (2015) Ketamine (INN) Update Review Report. https://www.who.int/medicines/access/controlledsubstances/6_1_Ketamine_Update_Review.pdf. Accessed 8 Aug 2019

  84. World Health Organization (2018) Depression. https://www.who.int/news-room/fact-sheets/detail/depression. Accessed 16 Jan 2021

  85. Xu Y, Hackett M, Carter G, Loo C, Gálvez V, Glozier N, Glue P, Lapidus K, McGirr A, Somogyi AA, Mitchell PB, Rodgers A (2016) Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. Int J Neuropsychopharmacol 19e(4):pyv124. https://doi.org/10.1093/ijnp/pyv124

    Article  Google Scholar 

  86. *Yanni Z, Zhang B, Zhou Y, Zheng W, Liu W, Wang C, Li H, Chen L, Yu L, Walter M, Li M, Li MD, Ning Y (2019) A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. J Affect Disord 251:205–212. https://doi.org/10.1016/j.jad.2019.03.071

    CAS  Article  Google Scholar 

  87. *Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:9

    Article  Google Scholar 

  88. *Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 71(11):939–946. https://doi.org/10.1016/j.biopsych.2011.12.010

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  89. *Zhang M, Rosenheck R, Lin X, Li Q, Zhou Y, Xiao Y, Huang X, Fan N, He H (2018) A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression. J Affect Disord 227:372–378. https://doi.org/10.1016/j.jad.2017.11.034

    CAS  Article  PubMed  Google Scholar 

  90. Zheng W, Cai D-B, Zheng W, Sim K, Ungvari GS, Peng X-J, Ning Y-P, Wang G, Xiang Y-T (2019a) Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies. Psychiatry Res 279:83–89. https://doi.org/10.1016/j.psychres.2019.07.006

    CAS  Article  PubMed  Google Scholar 

  91. Zheng W, Zhou Y-L, Liu W-J, Wang C-Y, Zhan Y-N, Li H-Q, Chen L-J, Li MD, Ning Y-P (2019b) Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder. J Psychopharmacol 33(4):494–501. https://doi.org/10.1177/0269881119827811

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ashley A. Conley.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 231 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Conley, A.A., Norwood, A.E.Q., Hatvany, T.C. et al. Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis. Psychopharmacology 238, 1737–1752 (2021). https://doi.org/10.1007/s00213-021-05825-8

Download citation

Keywords

  • Major depressive episodes
  • Ketamine
  • Depression
  • MDD
  • Bipolar